Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 in Japanese patients with cervical dystonia
jRCT2031230690Phase 3Completed
- Sponsor
- Teijin Pharma
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of botulinum toxin type A in cervical dystonia (CD) and tardive dystonia (TD) (2 arms), sponsored by Teijin Pharma. Primary endpoint: Change from baseline in TWSTRS total score at 4 weeks after the first injection. Started Apr 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
cervical dystonia (CD)tardive dystonia (TD)
Beyond the preview
Go deeper on jRCT2031230690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230690.